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Abstract
Prescription of direct oral anticoagulants (DOAC) compared to warfarin for treating atrial
fibrillation patients have increased substantially since their introduction in the England’s
National Health Service. Assessment of the risk of strokes and bleeds in relation to the
large-scale uptake in DOACs compared to warfarin at the clinical commissioning group
(CCG) level needs to be carried out. Publicly available- aggregated, CCG level, multi-source
health and prescription records data were interrogated to investigate the association
between prescription rate of DOACs and stroke/ bleed events during the period of 2013 to
2016. Variability of prescription rates and patient numbers across 208 CCGs were used to
infer the effect of DOACs on stroke and bleed risk. Relative risk (RR) and 95% credible inter-
vals (CI) were estimated using Markov chain Monte Carlo approach in JAGS. During the
study period, the proportion of DOAC prescriptions increased at an average rate of 122%
per annum. DOAC prescription was association with a 50% reduction in ischaemic (RR =
0.48, 95% CI = 0.39, 0.57) and haemorrhagic stroke (RR = 0.50, 95% CI = 0.26–0.77). In
contrast, DOAC prescription reached significant association with reduction in gastrointesti-
nal bleeds (RR = 0.86, 95% CI = 0.73–0.98) but not clinically relevant bleeds (RR = 0.95,
95% CI = 0.85–1.05). Sex stratified data showed significant association between DOAC pre-
scription and reduction in haemorrhagic stroke risk (RR = 0.40, 95% CI = 0.28–0.52) and
gastrointestinal bleeds (RR = 0.76, 95% CI = 0.63–0.93) in males only. Age stratified data
suggested significant association with reduction in risk of both ischaemic and haemorrhagic
strokes in patients aged 70 years and above, and reduction in risk of clinically relevant and
gastrointestinal bleeds in patients aged 70–79 years only. Publicly available health and pre-
scription data for the English population indicates reduction in stroke and bleed risk in spe-
cific age and sex sub-groups with the uptake of DOACs compared to warfarin between 2013
and 2016.
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Introduction
It is estimated that approximately 1.4 million people in England, which is equal to 2.5% of the
population, have atrial fibrillation (AF) [1]. Antiplatelet agents are deemed ineffective at reduc-
ing risk of stroke in AF patients [2]; thereby necessitating long-term anticoagulation using
alternative medications. Warfarin has been the mainstay of anticoagulation for the better part
of the last 60 years. However, in the past 8 years, its use has been gradually replaced by a new
class of anticoagulants called direct oral anticoagulants (DOACs) that includes dabigatran, riv-
aroxaban, apixaban and edoxaban. Unlike warfarin, DOACs have a wider therapeutic window,
can be prescribed at set doses, have faster onset and offset of action and generally do not
require patient monitoring for the degree of anticoagulation. Due to these attributes, DOAC
prescriptions have increased dramatically in the UK primary care with them accounting for
approximately 56% of all first-time oral anticoagulant prescriptions [3].
A series of large-scale randomized controlled trials (RCT) and subsequent meta-analysis of
these trials have established non-inferiority of DOACs for stroke prevention and superiority
for reducing haemorrhagic events in AF patients, compared to warfarin [4–8]. However, there
have been residual concerns about the safety and efficacy of DOACs compared to warfarin in
the real world scenario, where a broad range of patients are treated with anticoagulants. Fur-
thermore, a major uptake of DOACs in clinical practice in the UK has put a significant burden
on the healthcare budget; expenditure of anticoagulants rose by over a £100 million in 2016
with the estimate for the costs to rise to £1 billion per year by 2020 [9]. Lastly, a recent analysis
of adherence in England based on a representative review of repeat prescription issuance sug-
gests poor adherence with DOACs compared to warfarin [9]. A similar result has been
reported in Canada where approximately one in three patients were non-persistent to dabiga-
tran and rivaroxaban within 6 months from initiation [10]. Both results could be attributed to
the lack of routine monitoring requirement for DOACs in contrast to warfarin.
Despite these concerns, a prospective patient-level study by Green et al. in the English gen-
eral population from 2013–2016 showed that patients on DOACs were associated with lower
odds of an intracranial haemorrhage versus gastrointestinal (GI) bleeding, compared to warfa-
rin [11]. A more in-depth patient-level prospective study by Vinogradova et al. in the English
population between 2011 and 2016 showed that apixaban was the safest drug amongst the
DOACs compared to warfarin, with reduced risk of clinically relevant bleeding, intracranial
bleeding and GI bleeding [12]. Together, these results suggest concordance of safety results
between the RCTs and the real world population at patient-level. However, it is yet unclear
whether the mass uptake of DOACs led to a significant improvement in stroke and bleed rates
in England.
Following the re-organisation of the England’s National Health Service (NHS) in 2012,
decisions on routine clinical policies have been determined at individual clinical commission-
ing group (CCG) level in England, with each responsible for approximately 100,000–900,000
people [13]. This offered a natural experiment to assess the association between DOAC pre-
scription and risk of stroke/ bleed events in AF patients at the CCG level between 2013 and
2016, in order to detect risk-benefit of large scale uptake in DOAC prescription. We used
aggregated, CCG level, multi-source health records data to investigate these associations and
provide separate results for strokes and bleeds, with further stratification by sex and age. We
used a Bayesian approach whereby, variability of the aggregate number of DOAC prescriptions
and aggregate number of stroke/ bleed events across 208 CCGs was used to infer the associa-
tion between DOACs versus warfarin prescription and stroke/ bleed risk.
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Materials and methods
Eligibility and data collection
A comprehensive set of aggregated English national data was compiled from various databases
for the duration of 2013 to 2016, since no single database exists which contains all relevant
information (Fig 1).
CCG level aggregate number of episodes of hospitalised non valvular AF-related stroke in
England were accessed from the Hospital Episodes Statistics (HES) database (https://digital.
nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-
statistics). HES database contains details of hospital admissions, outpatient appointments and
accidents and emergency attendances at the NHS England hospitals. Aggregated yearly counts
of patients diagnosed with non-valvular AF related stroke or bleed (AF codes and hospital
Fig 1. STROBE diagram depicting analytical cohorts and their associated time frames. HES data indicates the total number of hospital episodes of AF patients
on long term oral anticoagulation with either a stroke or a bleed between 2013 and 2016 across all CCGs in England. QOF data indicates the total number of AF
patients and the total number of AF patients on an oral anticoagulation treatment in primary care for a given year across all CCGs. QOF prescription data indicates
the total number of warfarin and DOAC prescriptions made across all CCGs for a given year. HES = Hospital Episode Statistics, QOF = Quality Outcomes
Framework, AF = Atrial fibrillation, DOAC = direct oral anticoagulant, OAC = oral anticoagulation. � Total episodes consisting of stroke and bleed episodes in AF
patients on long term anticoagulation in the Hospital Episode Statistics database between 2013 and 2016.
https://doi.org/10.1371/journal.pone.0218878.g001
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admission ICD-10 codes in S1 Table), who were on an anticoagulation treatment at the time
of hospital admission (ICD-10 code: Z92.1) or had a clinical history of an anticoagulation
treatment before the time of admission (ICD-10 code: Y44.2) were extracted from HES data
between 2013 and 2016. Aggregate counts were further stratified by stroke type (ischaemic and
haemorrhagic), bleed type (gastrointestinal (GI) and clinically relevant), age groups (<60, 60–
69, 70–79, 80–89 and�90 years at the time of admission) and sex (male or female).
The English CCG level aggregate number of AF patients (AF001 code) and number of AF
patients on an oral anticoagulation were derived from the Clinical Domain of the Quality and
Outcomes Framework (QOF) database (https://qof.digital.nhs.uk) for the period of 2013 to
2016. QOF is a national primary care database covering all primary care practices in England
and collects prevalence and treatment data on numerous conditions, including AF. CCG-level
annual summary concerning the uptake of oral anticoagulants for patients residing in England
with a moderate to high risk of stroke measured either with CHADS2 score�1 for the period
2013–2015 and CHA2DS2-VASc score�2 for the period 2015–2016 were obtained from the
QOF database. Furthermore, annual aggregate number of warfarin and DOAC prescriptions
made at the primary care level within each CCG were also derived from QOF database. Lastly,
CCG level aggregate number of AF patients and number of patients an on oral anticoagulant
were stratified into age groups and sex strata with data available from The Health Improve-
ment Network (THIN) database (http://www.ucl.ac.uk/pcph/research/thin-database/
database). THIN database collects primary care electronic health records of 11.1 million
patients from 562 general practices in the UK. The database houses anonymised patient level
medical diagnoses and treatment data, including AF and oral anticoagulant prescription. Esti-
mates of the number of patients in each strata for each CCG were derived by multiplying the
aggregate number of patients in the QOF database with the proportion of patients in a given
strata from THIN database (Stratification methodology in S1 Table).
Ethics approval was not required for the current study as the data is publicly available for
analysis by the NHS Digital. All raw data is available in S1 File.
Data synthesis and statistical analysis
CCGs where the aggregate value for stroke or bleed event within any sub-group was 5�, indi-
cated that there were fewer than 5 events in that sub-group within a given year. Access to the
true number of events for these sub-groups was not available due to the risk of patient identifi-
cation, hence, the values for these CCGs were rounded off to 5.
Pairwise comparison of mean values of all CCGs across the 3 years was carried out using
two-sided Wilcoxon signed rank sum test. The relationship between the total number of AF
patients on anticoagulation and stroke or bleed rates for all CCGs between 2013 and 2016 were
modelled using non-parametric local-linear regression using Gaussian kernel and 300 boot-
strap replications; using the -npregress- package in Stata v15. Effect size output from the non-
parametric regression was presented as average marginal effect (as detailed in [14]). Relation-
ship was measured using Spearman’s rank correlation coefficient.
The relationship between DOAC prescription and stroke or bleed risk, was assessed using a
Markov chain Monte Carlo (MCMC) approach implemented in JAGS version 4.3.0 [15].
MCMC approach was utilised due to the availability of only CCG level summary stroke/ bleed
event and anticoagulant prescription data rather than a patient-level data. In the absence of
patient level data, MCMC, a Bayesian inference approach is useful as it allows to approximate
aspects of posterior distributions that otherwise cannot be directly calculated. One critical
assumption was made for the model used in the MCMC analysis: the probability of an age or
sex stratified patient being treated with a DOAC was equal to the probability of an unstratified
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patient being treated with a DOAC within a given CCG, in the period of interest (MCMC
codes included in S2 File). A total of 12,500 iterations, which included 2,500 iterations for
burn-in, were used for each analysis. The results were presented as relative risk (RR) and 95%
credible intervals (CI). We refer to the posterior credible interval overlapping RR value of 1 as
non-significant. MCMC analyses were carried out for the overall dataset as well as age and sex
stratified datasets. Data organisation was carried out in Stata v15 (Stata Corp, Texas, USA) and
JAGS was run in R programming environment v3.5.1 (https://cran.r-project.org/).
Results
Study population
The present study analysed CCG level summary stroke, bleeds and oral anticoagulation pre-
scription data from 208 CCGs in England, UK, across 2013 to 2016 (Table 1). Throughout the
3 years, there was an overall increase in the number of AF patients on anticoagulation (P
<0.0001), with the largest increase observed in 2015–2016. Concurrently, there was an
increase in the number of anticoagulation prescriptions, with the mean proportion of DOAC
prescriptions increasing from 4.4% to 21.4% during this period (P<0.0001), suggesting an
average increase in the proportion of DOAC prescription by 122% per annum. Whilst the
overall number of strokes and bleeds have increased, the rate of strokes and bleeds per 1000
AF patients on anticoagulation have decreased during this period suggesting an inverse rela-
tionship between number of people on anticoagulation and stroke/ bleed rates (Stroke rate
average marginal effect = -0.004 (-0.005, -0.002), p<0.001; Bleed rate average marginal effect =
-0.006 (-0.007, -0.005), p<0.001; S1 Fig and S2 Fig).
Association between DOAC prescription and stroke risk
Analysis across all 3 years showed a 50% reduction in risk of overall stroke associated with
DOAC prescription (RR = 0.49, 95% CI = 0.41–0.58; Fig 2A), compared with warfarin pre-
scription. Stroke-type specific analysis showed approximately 50% decrease in both ischaemic
stroke (RR = 0.48, 95% CI = 0.39, 0.57) and haemorrhagic stroke (RR = 0.50, 95% CI = 0.26–
0.77) with DOAC prescription.
Females had lower risk of overall stroke and ischaemic stroke compared to males when pre-
scribed a DOAC, compared to warfarin (Fig 2B). However, whilst males had 60% reduction in
haemorrhagic stroke risk when prescribed a DOAC (RR = 0.40, 95% CI = 0.28–0.52; Fig 2B), a
non-significant inverse association for risk reduction in females was observed (RR = 0.56, 95%
CI = 0.13–1.03).
Interestingly, AF patients above the age of 70 years observed approximately 40–50% reduc-
tion in stroke risk (both ischaemic and haemorrhagic) when prescribed a DOAC compared to
warfarin, with the exception of AF patients above 90 years of age who showed a trend for an
increased risk of haemorrhagic strokes when prescribed a DOAC (Fig 2C). Relative risk for
patients under the age of 70 years showed extremely large confidence intervals suggesting low
variability in the prescription rates and patient numbers, which did not allow estimation of rel-
ative risk accurately.
Association between DOAC prescription and bleed risk
Unlike strokes, analysis across all 3 years showed a non-significant association between bleed
risk and DOAC prescription compared to warfarin (All bleeds RR = 0.92, 95% CI = 0.84–1.00;
Clinically relevant bleeds RR = 0.95, 95% CI = 0.85–1.05; Fig 3A). However, a modest decrease
Safety and efficacy of DOAC prescription in atrial fibrillation patients in NHS England
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of approximately 14% was observed for GI bleed risk with DOAC prescription (RR = 0.86,
95% CI = 0.73–0.98).
Stratification by sex suggested approximately 10–20% decrease in all bleeds and GI
bleeds risk for males with DOAC prescription compared to warfarin (All bleeds RR = 0.89,
95% CI = 0.79–0.99; GI bleeds RR = 0.76, 95% CI = 0.63–0.93; Fig 3B). In contrast, no risk
reduction for all, clinically relevant or GI bleeds were observed for females with DOAC use
(Fig 3B).
Lastly, stratification by age groups showed a reduced risk of bleeds in the age group 70–79
years only with DOAC prescription compared to warfarin (All bleeds RR = 0.79, 95%
CI = 0.66–0.92; Clinically relevant bleeds RR = 0.82, 95% CI = 0.66–0.98; GI bleeds RR = 0.69,
95% CI = 0.50–0.90; Fig 3C). Interestingly, a trend for an increase in bleed risk was observed
in patients above the age of 80 years with DOAC use, however, none of the associations were
defined to be significant (Fig 3C).
Table 1. Summary statistics of the study population.
Year P-valueg
2013–2014 2014–2015 2015–2016
Number of CCGs � (n) 209 209 209 -
Total AF patients a (mean, SD per CCG) 4213 (2704) 4417 (2844) 4704 (3014) <0.0001
AF patients on anticoagulation b (mean, SD per CCG) 1734 (1120) 1815 (1153) 2995 (1938) <0.0001
Total number of anticoagulant prescriptions c
(mean, SD per CCG)
113318 (87073) 125875 (96336) 140040 (105933) <0.0001
Proportion of warfarin prescriptions d (mean, SD per CCG) 95.6 (4.6) 89.3 (7.5) 78.6 (9.6) <0.0001
Proportion of DOAC prescriptions d
(mean, SD per CCG)
4.4 (4.6) 10.7 (7.5) 21.4 (9.6) <0.0001
Number of All strokes e
(mean, SD per CCG)
66.9 (43.6) 67.5 (42.5) 71.3 (44.4) 0.29h and <0.0001
Number of Ischaemic strokes (mean, SD per CCG) 59.9 (39.4) 59.6 (37.9) 62.6 (39.4) 0.95h and 0.004
Number of Haemorrhagic strokes
(mean, SD per CCG)
8.3 (5.2) 9.0 (5.6) 9.7 (6.2) <0.003
Total number of All bleedsf
(mean, SD per CCG)
117.2 (73.8) 127.9 (80.5) 141.9 (89.1) <0.0001
Number of Clinically relevant bleeds
(mean, SD per CCG)
70.4 (46.1) 75.6 (49.3) 83.9 (53.7) <0.0001
Number of GI bleeds
(mean, SD per CCG)
50.4 (32.1) 56.4 (36.3) 62.8 (40.1) <0.0001
� Number of CCGs included in the final analysis was 208; Newcastle Gateshead CCG was not present in the year 2013–2014.
a Aggregate number of patients registered at the GP practice with non-valvular atrial fibrillation (AF001 code) in the QOF database
b Aggregate number of patients with CHADS2 score of 1 or above (AF004) on anticoagulation therapy in 2013–2015 and number of patients with CHA2DS2-VASc
score of 2 or above (AF007) on anticoagulation therapy in 2015–2016. Data was obtained from QOF database.
c Aggregate number of oral anticoagulant prescription made in primary care. Data was obtained from QOF database.
d Proportion of the aggregate number of oral anticoagulant prescriptions that are either warfarin or DOACs. Data was obtained from QOF database.
e Sum of the aggregate number of ischaemic and haemorrhagic strokes data available in HES database.
f Sum of the aggregate number of clinically relevant and gastrointestinal bleeds data available in HES database.
g P-value calculated using pairwise Wilcoxon signed rank test
h P-value for pairwise Wilcoxon signed rank test for values from year 2013–2014 and 2014–2015.
CCG = Clinical Commissioning Groups, AF = Atrial Fibrillation, DOAC = Direct acting Oral Anticoagulants, SD = Standard Deviation, GI = Gastrointestinal,
HES = Hospital Episodes Statistics, QOF = Quality Outcomes Framework.
https://doi.org/10.1371/journal.pone.0218878.t001
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Discussion
In the present study, we aimed to assess association between DOAC versus warfarin prescrip-
tion with stroke and bleed events, during the period of 2013–2016 in England’s National
Health Service. Our analysis showed a 50% reduction in strokes, both ischaemic and haemor-
rhagic, with DOAC prescription compared to warfarin. However, a small but non-significant
reduction in bleed risk, both clinically relevant and GI, was observed with DOAC prescription
compared to warfarin. Stratification by sex and age showed stroke or bleed risk reduction in
specific sub-groups compared to warfarin, in particular reduction in stroke risk for males and
patients with age between 70–89 years, and reduction in bleed risk in patients with age
between 70–79 years only.
Whilst an inverse association between haemorrhagic strokes and DOAC prescription com-
pared with warfarin is congruent with the published trials and latest observational studies [4–
7, 11, 12, 16], the inverse association of ischaemic stroke with DOAC prescription rate com-
pared to warfarin is in contrast to the published results. This contrast however needs to be
interpreted with caution. During the study period of 2013–2016, clinical guideline by the
National Institute of Health and Care Excellence (NICE; CG180) in England recommended
cessation of anti-platelet use for treating AF patients in order to prevent strokes [2]. This lead
to a decrease in the use of anti-platelets for AF by 21.6% between 2011 and 2016 with a simul-
taneous increase in the use of DOACs from 0.1% in 2011 to 32.5% of all oral anticoagulation
use in 2016 in England [17]. Interestingly, prescription trend data from the GRASP-AF
(http://www.heartrhythmalliance.org/afa/uk/grasp-af), a tool used in primary care to assess
risk of AF related stroke and efficacy of treatment, between 2009 and 2012 shows an age-
dependent prescription of oral anticoagulants and antiplatelets, whereby for the CHADS2
scores of 1–6, the proportion prescribed an anticoagulant was lower in AF patients aged 80
and over than in those aged less than 80 years; a converse observation was made for antiplatelet
prescription [18]. Hence, it is plausible that the introduction of NICE CG180 guidance would
have steered a large proportion of patients aged 80 years and above, who have a higher
CHADS2 score and hence are at a higher risk of stroke compared to patients aged below 80
[19], from an antiplatelet to an anticoagulant treatment, most likely DOACs, during the cur-
rent study period. The switch in treatment would have likely reduced their risk of ischaemic
stroke, the outcome of which being an inverse association between DOAC prescription and
ischaemic stroke in the current study. However, assessment of this hypothesis is beyond the
remit of the current study and should be examined in future studies.
Interestingly, sex stratified data suggests both males and females having an inverse associa-
tion between ischaemic strokes and DOAC prescription, however, a statistically significant
inverse association for haemorrhagic stroke with DOAC prescription is restricted to males
only. The lack of significant association for females could be due to the lack of variability in the
prescription rates and patient numbers; as can be observed with large credible intervals (see
Fig 2B). A similar issue is observed in the age stratified stroke risk analysis for patients below
the age of 70.
In contrast to strokes, DOAC prescription showed a small inverse but statistically non-sig-
nificant association with bleeds. For bleed type stratified data, however, inverse association
between DOAC prescription and GI bleeds reached significance. Furthermore, sex stratified
bleed data suggested a significant inverse association between GI bleeds and DOAC use that is
Fig 2. Association between DOAC versus warfarin prescription and (A) overall stroke risk, (B) sex stratified
stroke risk and (C) age stratified stroke risk. RR = relative risk, CI = credible intervals. � Sub-group estimate with
high autocorrelation within the MCMC model.
https://doi.org/10.1371/journal.pone.0218878.g002
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restricted to males only, in our study. This potentially novel observation could be explained by
sex specific differences in the prescription of specific DOACs. Previous observational study
and meta-analysis have shown inverse relationship between GI bleeds with apixaban and not
rivaroxaban and dabigatran use in the AF patients [12, 16]. In the UK wide observational
study by Green et al., approximately 50% of the dabigatran and rivaroxaban prescriptions were
made to males, whereas, 61% of the apixaban prescriptions were made to males [11]. As apixa-
ban has been associated with a lower risk of GI bleeds compared to warfarin, it is possible that
the males may have derived greater benefit than females for reduction in GI bleeds. Lastly, age
stratified data showed significant risk reduction for clinically relevant and GI bleeds to be asso-
ciated with DOAC use in patients with age 70–79 years only. Beyond 79 years, there is a sug-
gestion for a trend of an increase in bleed risk with DOAC use. This trend has previously been
reported by Abraham et al., whereby they observed an increased risk of GI bleeds in AF
patients with age more than 76 years, taking dabigatran (HR = 2.49, 95% CI = 1.61–3.83) or
rivaroxaban (HR = 2.91, 95% CI = 1.65–4.81) compared to warfarin [20].
Of note, the code used in the QOF database which indicated the aggregate number of AF
patients receiving an oral anticoagulation treatment changed from AF004 in 2013–2015 to
AF007 in 2015–2016. The change in the code saw a corresponding minor increase in the pro-
portion of moderate to high risk AF patients on anticoagulation from 84% in 2013–2015 to
87% in 2015–2016 but a large increase in the proportion of overall AF population that receives
anticoagulation from 41% in 2013–2015 to 63% in 2015–2016. This substantial increase can be
attributed to the ability of CHA2DS2-VASc score to enable identification of a larger number
of AF patients for whom oral anticoagulation therapy is recommended compared to CHADS2
score [21]. Nonetheless, this wouldn’t have impacted the analysis as the analysis model
required data on the moderate to high risk AF patients on oral anticoagulation rather than the
overall number of AF patients in each CCG (see S2 File).
Whilst the current study has strengths such as systematic coverage of a single national
health system, we acknowledge its limitations. First, the data were aggregated and not linked at
the patient level, which precluded us from carrying out patient-level analysis and adjust for all
possible confounding factors over the study period. This may potentially lead to our findings
being incorrectly attributed or interpreted to the individual patient level. Second, our models
assumed that DOAC prescription rate was same across all age and sex sub-groups for a given
CCG and time period. In contrast to this, previous observational studies have shown that the
probability of DOAC prescription differs between age-groups and sexes [11, 12]. Third, some
of the CCGs where the stroke and/ or bleed events in specific sub-groups were less than 5 for a
given year, the CCGs were coded as having 5 events. Knowledge of the true number of events
was restricted to protect patient confidentiality. However, this approach may have reduced
data variability, especially in certain age and sex subgroups. This may have not only reduced
the accuracy of relative risk estimation but may have inflated risk estimates for certain sub-
groups. Fourth, whilst patients were selected based on the hospital codes describing them on
either being on long term anticoagulation (ICD-10 code- Z92.1) and/ or having an adverse
effect of anticoagulation medication in therapeutic use (ICD-10 code- Y44.2), it was not possi-
ble to gather detail on anticoagulation therapy duration. This could have implications on the
bleeding risk, as the risk of bleeding is highest in the initial few months after initiation of antic-
oagulation therapy [22, 23].
Fig 3. Association between DOAC versus warfarin prescription and (A) overall bleed risk, (B) sex stratified bleed
risk and (C) age stratified bleed risk. RR = relative risk, CI = credible intervals. � Sub-group estimate with high
autocorrelation within the MCMC model.
https://doi.org/10.1371/journal.pone.0218878.g003
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In summary, our results suggest reduction in ischaemic and haemorrhagic stroke risk with
increase in prescription of DOACs between 2013 and 2016 in England. Furthermore, a small
but significant reduction in GI bleed risk is observed in specific subgroups, such as males and
patients between 70–79 years of age, with increase in DOAC prescription.
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